These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 17604883)

  • 1. Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity.
    Mayol K; Munier S; Beck A; Verrier B; Guillon C
    Vaccine; 2007 Aug; 25(32):6047-60. PubMed ID: 17604883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
    Re MC; Gibellini D; Vitone F; La Placa M
    New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
    Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
    Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
    Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
    Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-7 and the HIV Tat protein act synergistically to down-regulate CD127 expression on CD8 T cells.
    Faller E; Kakal J; Kumar R; Macpherson P
    Int Immunol; 2009 Mar; 21(3):203-16. PubMed ID: 19147839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application.
    Caputo A; Brocca-Cofano E; Castaldello A; De Michele R; Altavilla G; Marchisio M; Gavioli R; Rolen U; Chiarantini L; Cerasi A; Dominici S; Magnani M; Cafaro A; Sparnacci K; Laus M; Tondelli L; Ensoli B
    Vaccine; 2004 Jul; 22(21-22):2910-24. PubMed ID: 15246628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
    Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
    Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.
    Ensoli B; Fiorelli V; Ensoli F; Cafaro A; Titti F; Buttò S; Monini P; Magnani M; Caputo A; Garaci E
    AIDS; 2006 Nov; 20(18):2245-61. PubMed ID: 17117011
    [No Abstract]   [Full Text] [Related]  

  • 11. Tat toxoid: its potential role as an HIV vaccine.
    Lambert J
    J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
    Fanales-Belasio E; Moretti S; Fiorelli V; Tripiciano A; Pavone Cossut MR; Scoglio A; Collacchi B; Nappi F; Macchia I; Bellino S; Francavilla V; Caputo A; Barillari G; Magnani M; Laguardia ME; Cafaro A; Titti F; Monini P; Ensoli F; Ensoli B
    J Immunol; 2009 Mar; 182(5):2888-97. PubMed ID: 19234184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
    Bråve A; Hinkula J; Cafaro A; Eriksson LE; Srivastava IK; Magnani M; Ensoli B; Barnett SW; Wahren B; Rollman E
    Vaccine; 2007 Sep; 25(39-40):6882-90. PubMed ID: 17707956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some recent results on HIV pathogenesis with implications for therapy and vaccines.
    Gallo RC; Garzino-Demo A
    Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1101-4. PubMed ID: 11838957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
    Gallo RC; Burny A; Zagury D
    DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination.
    Kim SG; Park MY; Kim CH; Sohn HJ; Kim HS; Park JS; Kim HJ; Oh ST; Kim TG
    Vaccine; 2008 Nov; 26(50):6433-40. PubMed ID: 18812201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Tat vaccines.
    Ensoli B; Cafaro A
    Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application.
    Betti M; Voltan R; Marchisio M; Mantovani I; Boarini C; Nappi F; Ensoli B; Caputo A
    Vaccine; 2001 May; 19(25-26):3408-19. PubMed ID: 11348705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prospective preventative HIV vaccine based on modified poliovirus.
    Zhang YD; Lu XL; Li NF
    Med Hypotheses; 2007; 68(6):1258-61. PubMed ID: 17196342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.